Connect Portal

TitleJournal/ConferenceYearhf:tax:journalhf:tax:testhf:tax:tumor_typehf:tax:biomarkerhf:tax:publication_year
Integration of multiple immune-associated biomarkers facilitates classification of solid tumors by primary immune escape mode and prediction of patient outcomesSOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 20222022society-for-immunotherapy-of-cancer-sitc-2022comprehensive-genomic-and-immune-profilingnon-small-cell-lung-cancercancer-testis-antigen-burden cell-proliferation-signature pd-l1-ihc tumor-immunogenic-signature tumor-mutational-burden2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaJournal for ImmunoTherapy of Cancer2022journal-for-immunotherapy-of-cancerrnaseqrenal-cell-carcinomaimmune-profile2022
Sensitivity and concordance of CD274(PD-L1) expression by RNA sequencing (RNA-seq) in comparison with three PD-L1 immunohistochemistry methods in head and neck squamous cell carcinoma (HNSCC)SOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 20222022society-for-immunotherapy-of-cancer-sitc-2022rnaseqsolid-tumorsimmune-profile2022
The immune expression landscape of solid tumors with tertiary lymphoid structuresSOCIETY FOR IMMUNOTHERAPY OF CANCER SITC 20222022society-for-immunotherapy-of-cancer-sitc-2022pd-l1-ihc rnaseqsolid-tumorsimmune-profile pd-l1-ihc2022
Comprehensive genomic and immune profiling of non-small cell lung cancer brain metastases reveals low tumor inflammation and elevated cancer testis antigen burdenSociety for NeuroOncology2022society-for-neurooncologydna-seq rnaseqnon-small-cell-lung-cancerimmune-profile mutational-profile2022
Combined Low-pass Whole Genome and Targeted Sequencing Identifies Causative Mutations and Associated Genomic Scarring Indicative of Homologous Recombination Deficiency2022 AMP Annual Meeting20222022-amp-annual-meetingoasolid-tumors2022
Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC)American Society of Clinical Oncology2022american-society-of-clinical-oncologydna-seq msi pd-l1-ihc rnaseq tmbnon-small-cell-lung-cancerclinical-decision-making clinical-utility pd-l12022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapyCancer Treatment Reviews2022cancer-treatment-reviewspd-l1-ihcsolid-tumorsctla-4 pd-l12022
Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance2022 ASCO Annual Meeting20222022-asco-annual-meetingpd-l1-ihc rnaseqsolid-tumorsctla-4 lag3 msi pd-l1 tigit tmb2022
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers2022 ASCO Annual Meeting20222022-asco-annual-meetingpd-l1-ihc rnaseqsolid-tumorsctla-4 lag3 pd-l1 tmb2022
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC2022 ASCO Annual Meeting20222022-asco-annual-meetingpd-l1-ihc rnaseqsolid-tumorspd-l12022
PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC)American Association of Cancer Research 20222022american-association-of-cancer-research-2022pd-l1-ihc rnaseqnon-small-cell-lung-cancerpd-l12022
Cancer testis antigen burden: pan-cancer distribution and survival implicationsAmerican Association of Cancer Research 20222022american-association-of-cancer-research-2022rnaseqsolid-tumorsct-antigens2022
Checkpoint coexpression landscape in gastroesophageal adenocarcinomaInternational Gastric Cancer Congress 20222022international-gastric-cancer-congress-2022rnaseqsolid-tumorsimmune-profile tumor-immunogenic-signature tumor-inflammation2022
Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLCJournal of Thoracic Oncology - Clinical and Research Reports2021journal-of-thoracic-oncology-clinical-and-research-reportsrnaseqnon-small-cell-lung-cancerbmi2021
Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal AdenocarcinomaJournal of Personalized Medicine2021journal-of-personalized-medicinepd-l1-ihc rnaseqgi-tumorsimmune-profile2021
A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumorsPLOS ONE2021plos-onedna-seq msi rnaseq tmbsolid-tumorsanalytical-validation2021
Molecular profiling of metastatic renal cell carcinoma treated with ipilimumab-nivolumabInternational Kidney Cancer Symposium (2021 IKCS)2021international-kidney-cancer-symposium-2021-ikcspd-l1-ihc rnaseqkidneyimmune-profile pd-l12021
Immune and cancer testis antigen landscape in sarcomaConnective Tissue Oncology Society (CTOS 2021)2021connective-tissue-oncology-society-ctos-2021pd-l1-ihc rnaseqsarcomact-antigens immune-profile pd-l12021
Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumorsSITC’s 36th Annual Meeting2021sitcs-36th-annual-meetingdna-seq ihc rnaseq tmbsolid-tumorsclinical-decision-making immune-profile2021
Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumorsSITC’s 36th Annual Meeting2021sitcs-36th-annual-meetingrnaseqsolid-tumorsct-antigens2021
Novel immunotherapeutic targets in cancer of unknown primary (CUP)SITC’s 36th Annual Meeting2021sitcs-36th-annual-meetingdna-seq pd-l1-ihc rnaseq tmbsolid-tumorsclinical-decision-making immune-profile2021
Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization ProjectAnnals of Oncology2021annals-of-oncologytmbsolid-tumorstmb2021
Cancer/testis antigen expression landscape in gastroesophageal adenocarcinomaESMO 20212021esmo-2021rnaseqgi-tumors solid-tumorsbmi ct-antigens2021
Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implicationESMO 20212021esmo-2021dna-seq msi pd-l1-ihcsolid-tumorspd-l1 tmb2021
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceBritish Journal of Cancer2021british-journal-of-cancerocpurothelial-carcinomafgfr2021
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and responseBiomarker Research2021biomarker-researchihc msi pd-l1-ihc rnaseq tmblung-cancer non-small-cell-lung-cancerct-antigens immune-profile infiltrated-tumors tumor-immunogenic-signature2021
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regionsGenome Biology2021genome-biologydna-seqsolid-tumorsanalytical-validation comparator-study2021
Visceral Obesity Promotes Lung Cancer Progression – Towards Resolution of the Obesity Paradox in Lung CancerJournal of Thoracic Oncology2021journal-of-thoracic-oncologyrnaseqlung-cancer non-small-cell-lung-cancer solid-tumorsimmune-profile inflammation2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncologyNature Biotechnology2021nature-biotechnologydna-seqcirculating-tumor-dna ctdnactdna predictive-algorithm validation2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsNature Communications2021nature-communicationsdna-seq rnaseqcolorectalimmune-profile tmb2021
Immune profiling and immunotherapeutic targets in pancreatic cancerAnnals of Translational Medicine2021annals-of-translational-medicinepancreatic-cancer solid-tumorsimmune-profile2021
Cancer-testis antigen detection by targeted RNA sequencing2020 AMP Annual Meeting20202020-amp-annual-meetingrnaseqsolid-tumorsct-antigens2020
Cancer testis antigen co-expression landscape in solid tumorsSITC's 35th Annual Meeting (2020)2020sitcs-35th-annual-meeting-2020rnaseqsolid-tumorsct-antigens2020
PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancerSITC's 35th Annual Meeting (2020)2020sitcs-35th-annual-meeting-2020ihc rnaseqnon-small-cell-lung-cancerpd-l12020
Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRASSITC's 35th Annual Meeting (2020)2020sitcs-35th-annual-meeting-2020dna-seq tmbnon-small-cell-lung-canceralk egfr kras stk11 tmb tp532020
Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical PracticeClinical Therapeutics2020clinical-therapeuticsnon-small-cell-lung-cancerimmune-profile2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsOncoImmunology2020oncoimmunologymsi pd-l1-ihc rnaseq tmbrenal-cell-carcinomacell-proliferation2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneityOncoImmunology2020oncoimmunologymsi pd-l1-ihc rnaseq tmbsolid-tumorsimmune-profile2020
Distinct pathways of DC-induced CD8+ T cell differentiation revealed by single-cell mRNA sequencing analysisAACR Annual Meeting 20202020aacr-annual-meeting-2020rnaseqimmune-cellsimmune-profile2020
Single-cell mRNA sequencing analysis of the synergistic impact of double-stranded RNA (dsRNA) and IFNa on human monocyte-derived macrophagesAACR Annual Meeting 20202020aacr-annual-meeting-2020rnaseqimmune-cellsimmune-profile2020
Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies2020 Genitourinary Cancers Symposium20202020-genitourinary-cancers-symposiumrnaseqbladder-cancercomparator-study2020
Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies2020 ASCO-SITC Clinical Immuno-Oncology Symposium20202020-asco-sitc-clinical-immuno-oncology-symposiumrnaseqsolid-tumorscell-proliferation inflammation tumor-immunogenic-signature2020
Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer2020 ASCO-SITC Clinical Immuno-Oncology Symposium20202020-asco-sitc-clinical-immuno-oncology-symposiumrnaseqlung-cancerinflammation tumor-immunogenic-signature2020
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for CancerFrontiers in Immunology2020frontiers-in-immunologytcrbmelanomactla-4 tcr%ce%b22020
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assayOncotarget2019oncotargetmsisolid-tumorsanalytical-validation2019
Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive TumorsSITC's 34th Annual Meeting (2019)2019sitcs-34th-annual-meeting-2019msi pd-l1-ihc rnaseq tmbsolid-tumorsbispecifics tme2019
CT Antigens are Frequently Expressed in Non-Inflamed TumorsSITC's 34th Annual Meeting (2019)2019sitcs-34th-annual-meeting-2019msi pd-l1-ihc rnaseq tmbsolid-tumorsct-antigens tme2019
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire SequencingJournal of Immunotherapy and Precision Oncology2019journal-of-immunotherapy-and-precision-oncologytcrbperipheral-blood-leukocyteshaplotype-analysis tcr%ce%b22019
Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLCJournal of Thoracic Oncology2019journal-of-thoracic-oncologyrnaseqsolid-tumorsbmi immune-profile metformin2019
Oncologist uptake of comprehensive genomic profile guided targeted therapyOncotarget2019oncotargetocpsolid-tumorsclinical-decision-making clinical-utility2019
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinomaASCO-SITC Clinical Immuno-Oncology Symposium - 20192019asco-sitc-clinical-immuno-oncology-symposium-2019msi pd-l1-ihc rnaseq tmbrenal-cell-carcinomacell-proliferation patient-response tumor-inflammation2019
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC)ASCO-SITC Clinical Immuno-Oncology Symposium - 20192019asco-sitc-clinical-immuno-oncology-symposium-2019msi pd-l1-ihc rnaseq tmbrenal-cell-carcinomacell-proliferation patient-response tumor-inflammation2019
Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneityASCO-SITC Clinical Immuno-Oncology Symposium - 20192019asco-sitc-clinical-immuno-oncology-symposium-2019tmbsolid-tumorscomparator-study specimen-characteristics validation2019
RNA-sequencing reveals immunotherapy targets in gynecological cancerASCO-SITC Clinical Immuno-Oncology Symposium - 20192019asco-sitc-clinical-immuno-oncology-symposium-2019msi pd-l1-ihc rnaseq tmbgynocological-cancersimmune-profile immune-suppression2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsJournal for ImmunoTherapy of Cancer2019journal-for-immunotherapy-of-cancermsi pd-l1-ihc rnaseq tmbnon-small-cell-lung-cancercell-proliferation patient-survival2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJournal for ImmunoTherapy of Cancer2019journal-for-immunotherapy-of-cancerpd-l1-ihc rnaseqsolid-tumorscomparator-study patient-response pd-l12019
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencingBMC Medical Informatics and Decision Making2019bmc-medical-informatics-and-decision-makingocpsolid-tumorsclinical-decision-making clinical-utility2019
RNA-Expression Profiling Reveals Immunotherapy Targets in SarcomaJournal of Sarcoma Research2018journal-of-sarcoma-researchmsi pd-l1-ihc rnaseq tmbsarcomaimmune-profile myeloid-suppression2018
Identification of targets for prostate cancer immunotherapyThe Prostate2018the-prostatemsi pd-l1-ihc rnaseq tmbprostate-cancerimmune-profile2018
Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platformsASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018tmbsolid-tumorscomparator-study tmb2018
Identifying major immune subsets of GI tumors for clinical purposesSITC's 33rd Annual Meeting (2018)2018sitcs-33rd-annual-meeting-2018msi pd-l1-ihc rnaseq tmbgi-tumorsimmune-profile2018
Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testingSITC's 33rd Annual Meeting (2018)2018sitcs-33rd-annual-meeting-2018msisolid-tumorsanalytical-validation2018
Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung CancerASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018pd-l1-ihcnon-small-cell-lung-cancercell-proliferation patient-survival2018
Combination immunotherapy selection for non-PD-1 axis driven tumors2018 ASCO Annual Meeting20182018-asco-annual-meetingrnaseqsolid-tumorsimmune-profile2018
Combination immunotherapy selection for PD-1 axis driven tumors2018 ASCO Annual Meeting20182018-asco-annual-meetingrnaseqsolid-tumorsimmune-profile2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumabOncoImmunology2018oncoimmunologymsi pd-l1-ihc rnaseq tmburothelial-carcinomaimmune-profile patient-response pd-l22018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenJournal for ImmunoTherapy of Cancer2018journal-for-immunotherapy-of-cancermsi pd-l1-ihc rnaseq tmbmelanomapatient-survival tumor-inflammation2018
Chemokine expression signatures in infiltrated vs non-infiltrated tumorsAACR Annual Meeting 20182018aacr-annual-meeting-2018msi pd-l1-ihc rnaseq tmbsolid-tumorschemokines infiltrated-tumors tumor-infiltrating-lymphocytes2018
PD-L1 driven excluded phenotype in melanomaAACR Annual Meeting 20182018aacr-annual-meeting-2018msi pd-l1-ihc rnaseq tmbmelanomacd8 excluded-phenotype2018
Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seqAACR Annual Meeting 20182018aacr-annual-meeting-2018msi pd-l1-ihc rnaseq tmbsolid-tumorspatient-response pd-l12018
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint InhibitionASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018msi pd-l1-ihc rnaseq tmbsolid-tumorscd8 patient-response2018
Comprehensive Immune and Mutational Profile of MelanomaASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018oamelanomaimmune-profile mutational-profile2018
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in MelanomaASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018oamelanomactla4 patient-response2018
Lung Cancer Mutational Profile Correlates with Immune ProfileASCO-SITC Clinical Immuno-Oncology Symposium - 20182018asco-sitc-clinical-immuno-oncology-symposium-2018msi pd-l1-ihc rnaseq tmblung-cancerimmune-profile mutational-profile2018
Overexpression of Immunotherapeutic Targets in the Immune Desert PhenotypeSITC's 32nd Annual Meeting (2017)2017sitcs-32nd-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorsimmune-desert immune-profile2017
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠SITC's 32nd Annual Meeting (2017)2017sitcs-32nd-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorsimmune-profile2017
The Immune-Excluded Phenotype Beyond Colorectal CancerSITC's 32nd Annual Meeting (2017)2017sitcs-32nd-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorscd8 excluded-phenotype2017
Secondary Immunotherapeutic Targets In Inflamed TumorsSITC's 32nd Annual Meeting (2017)2017sitcs-32nd-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorsimmune-profile tumor-inflammation2017
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid TumorsThe Journal of Molecular Diagnostics2017the-journal-of-molecular-diagnosticsmsi pd-l1-ihc rnaseq tmbsolid-tumorsanalytical-validation2017
Algorithmic Prediction of Response to Checkpoint Inhibitors2017 ASCO Annual Meeting20172017-asco-annual-meetingrnaseqsolid-tumorspatient-response predicitve-algorithm2017
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint InhibitorsImmunology 20172017immunology-2017msi pd-l1-ihc rnaseq tmbmelanomapatient-response tumor-inflammation2017
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint InhibitorsImmunology 20172017immunology-2017msi pd-l1-ihc rnaseq tmbnon-small-cell-lung-cancerpatient-response tumor-inflammation2017
Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classificationAACR Annual Meeting 20172017aacr-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorsspecimen-characteristics validation2017
NGS reveals specimen characteristics have minimal impact on immune gene expression signatureAACR Annual Meeting 20172017aacr-annual-meeting-2017rnaseqspecimen-characteristics validation2017
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patientAACR Annual Meeting 20172017aacr-annual-meeting-2017msi pd-l1-ihc rnaseq tmbsolid-tumorsspecimen-characteristics validation2017
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors2017 ASCO Annual Meeting20172017-asco-annual-meetingmsi pd-l1-ihc rnaseq tmbanalytical-validation2017
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencingOncotarget2016oncotargetmsi pd-l1-ihc rnaseq tmbsolid-tumorscomparator-study specimen-characteristics validation2016
An Algorithmic Approach to Cancer Immune ProfilingSITC's 31st Annual Meeting (2016)2016sitcs-31st-annual-meeting-2016msi pd-l1-ihc rnaseq tmbsolid-tumorspatient-response predicitve-algorithm2016
Validation of a Custom RNA-Seq Approach to Cancer Immune ProfilingSITC's 31st Annual Meeting (2016)2016sitcs-31st-annual-meeting-2016msi pd-l1-ihc rnaseq tmbsolid-tumorscomparator-study specimen-characteristics validation2016